Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 25, 2024, At 4 pm Eastern Time
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on September 25, 2024, at 4:00 PM Eastern Time. The company, which focuses on developing cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, invites investors, advisors, and analysts to attend this interactive online event.
CEO Dr. David Koos will lead the presentation, providing updates on fiscal and scientific goals, progress on current programs, and the timeline for the anticipated HemaXellerate clinical phase I. Attendees will have the opportunity to ask questions in real-time during the 10-minute presentation.
Interested parties can register for the event through the provided link. An archived webcast will be available on EmergingGrowth.com for those unable to attend live.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) presenterà alla Emerging Growth Conference il 25 settembre 2024, alle 16:00 ora orientale. L'azienda, focalizzata sullo sviluppo di terapie cellulari, vaccini a RNA, terapie a RNA e DNA e farmaci a piccole molecole, invita investitori, consulenti e analisti a partecipare a questo evento interattivo online.
Il CEO Dr. David Koos guiderà la presentazione, fornendo aggiornamenti sugli obiettivi fiscali e scientifici, i progressi sui programmi attuali e la tempistica per la prevista fase clinica I di HemaXellerate. I partecipanti avranno l'opportunità di porre domande in tempo reale durante la presentazione di 10 minuti.
Le parti interessate possono registrarsi per l'evento tramite il link fornito. Un webcast registrato sarà disponibile su EmergingGrowth.com per coloro che non possono partecipare dal vivo.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) presentará en la Emerging Growth Conference el 25 de septiembre de 2024, a las 4:00 PM hora del Este. La compañía, que se centra en desarrollar terapias celulares, vacunas de ARN, terapias de ARN y ADN, y fármacos de pequeñas moléculas, invita a inversores, asesores y analistas a asistir a este evento interactivo en línea.
El CEO Dr. David Koos liderará la presentación, proporcionando actualizaciones sobre los objetivos fiscales y científicos, el progreso de los programas actuales y el calendario para la anticipada fase clínica I de HemaXellerate. Los asistentes tendrán la oportunidad de hacer preguntas en tiempo real durante la presentación de 10 minutos.
Las partes interesadas pueden registrarse para el evento a través del enlace proporcionado. Se dispondrá de una transmisión web archivada en EmergingGrowth.com para aquellos que no puedan asistir en vivo.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP)는 2024년 9월 25일, 동부 표준시 기준 오후 4시에 Emerging Growth Conference에서 발표할 예정입니다. 세포 치료, RNA 백신, RNA 및 DNA 치료제, 소분자 약물을 개발하는 데 주력하는 이 회사는 투자자, 고문 및 분석가를 초대하여 이 인터랙티브 온라인 이벤트에 참석하도록 합니다.
CEO Dr. David Koos가 발표를 이끌며, 재무 및 과학 목표, 현재 진행 중인 프로그램의 진척 상황, 그리고 예상되는 HemaXellerate 임상 1단계의 일정에 대한 업데이트를 제공할 것입니다. 참석자들은 10분 발표 동안 실시간으로 질문할 기회를 가질 수 있습니다.
관심 있는 분들은 제공된 링크를 통해 이벤트에 등록할 수 있습니다. 라이브로 참석하지 못한 분들을 위해 EmergingGrowth.com에서 아카이브된 웹캐스트를 이용할 수 있습니다.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) présentera à la Emerging Growth Conference le 25 septembre 2024 à 16h00, heure de l'Est. L'entreprise, qui se concentre sur le développement de thérapies cellulaires, de vaccins à ARN, de thérapies à ARN et ADN et de médicaments à petites molécules, invite les investisseurs, conseillers et analystes à participer à cet événement interactif en ligne.
Le PDG Dr. David Koos animera la présentation, fournissant des mises à jour sur les objectifs financiers et scientifiques, les avancées des programmes en cours et le calendrier de la phase clinique I de HemaXellerate attendue. Les participants auront l'opportunité de poser des questions en temps réel pendant la présentation de 10 minutes.
Les parties intéressées peuvent s'inscrire à l'événement via le lien fourni. Un webcast archivé sera disponible sur EmergingGrowth.com pour ceux qui ne peuvent pas assister en direct.
Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) wird am 25. September 2024 um 16:00 Uhr Eastern Time auf der Emerging Growth Conference präsentieren. Das Unternehmen, das sich auf die Entwicklung von Zelltherapien, RNA-Impfstoffen, RNA- und DNA-Therapeutika sowie kleinen Molekülarzneimitteln konzentriert, lädt Investoren, Berater und Analysten ein, an dieser interaktiven Online-Veranstaltung teilzunehmen.
CEO Dr. David Koos wird die Präsentation leiten und Updates zu den finanziellen und wissenschaftlichen Zielen, dem Fortschritt der aktuellen Programme sowie dem Zeitplan für die bevorstehende HemaXellerate klinische Phase I geben. Die Teilnehmer haben die Möglichkeit, während der 10-minütigen Präsentation Fragen in Echtzeit zu stellen.
Interessierte Parteien können sich über den bereitgestellten Link für die Veranstaltung registrieren. Eine archivierte Webcast wird auf EmergingGrowth.com verfügbar sein für diejenigen, die nicht live teilnehmen können.
- None.
- None.
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
SAN DIEGO, CA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on September 25, 2024 (https://emerginggrowth.com/conference/).
This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to get through as many of them as possible.
“We plan to use this time to update our shareholders on our fiscal and scientific goals for the upcoming year, discuss our progress on current programs and timeline regarding our anticipated HemaXellerate clinical phase I,” says Dr. David Koos, CEO and Chairman of the Company.
Regen BioPharma, Inc. will be presenting at 4:00 pm to 4:10 Eastern time on Wednesday September 25, 2024. Please register here to ensure you are able to attend the conference and receive any updates that are released
https://goto.webcasts.com/starthere.jsp?ei=1677125&tp_key=64e020ccee&sti=rgbp
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or
david.koos@regenbiopharma.com
X (formerly twitter): https: //x.com/TheRegenBio
FAQ
When is Regen BioPharma (RGBP) presenting at the Emerging Growth Conference?
What topics will Regen BioPharma (RGBP) discuss during the Emerging Growth Conference?
How can investors attend Regen BioPharma's (RGBP) presentation at the Emerging Growth Conference?
Will there be an opportunity to ask questions during Regen BioPharma's (RGBP) presentation?
What areas of biotechnology does Regen BioPharma (RGBP) focus on?
